| 产品描述: | TVB-3166 是一种口服有效,可逆和选择性脂肪酸合成酶 (FASN) 抑制剂,对于 FASN 和细胞棕榈酸酯合成的 IC50 分别为 42 nM 和 81 nM。TVB-3166 诱导细胞凋亡,并抑制体内异种移植肿瘤的生长。 |
| 靶点: |
IC50: 42 nM (FASN) and 81 nM (cellular palmitate synthesis) |
| 体外研究: |
TVB-3166 (0.001-10 μM; 24 hours) causes cell death in CALU-6 non-small-cell lung tumor cells with a cellular IC50 value of 0.10 μM. TVB-3166 (0.02 or 0.20 μM; 7 days) inhibits palmitate synthesis and tumor cell viability in a dose-dependent manner. TVB-3166 (0.2 μM; 48 hours) inhibits β-catenin pathway signal transduction and transcriptional activity. |
| 体内研究: |
TVB-3166 (Oral gavage; 30-100 mg/kg/day) inhibits xenograft tumor growth. TVB-3166 (Oral gavage; 30-100 mg/kg/day) has the concentration is approximately 3-fold higher in plasma than tumor. The 100 and 30 mg/kg groups had plasma and tumor concentrations of 7 and 2.9 μM, respectively. |
| 参考文献: |
1. Ventura R, et al. Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression. EBioMedicine. 2015 Jul 2;2(8):808-24. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.601 ml |
13.005 ml |
26.01 ml |
| 5 mM |
0.52 ml |
2.601 ml |
5.202 ml |
| 10 mM |
0.26 ml |
1.3 ml |
2.601 ml |
| 50 mM |
0.052 ml |
0.26 ml |
0.52 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |